Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

NYVAC vector modified by C7L viral gene insertion improves T cell immune responses and effectiveness against leishmaniasis.

Sánchez-Sampedro L, Mejías-Pérez E, S Sorzano CÓ, Nájera JL, Esteban M.

Virus Res. 2016 Jul 15;220:1-11. doi: 10.1016/j.virusres.2016.03.007. Epub 2016 Mar 29.

PMID:
27036935
2.

Suppression of NYVAC Infection in HeLa Cells Requires RNase L but Is Independent of Protein Kinase R Activity.

Fernández-Escobar M, Nájera JL, Baldanta S, Rodriguez D, Way M, Esteban M, Guerra S.

J Virol. 2015 Dec 9;90(4):2135-41. doi: 10.1128/JVI.02576-15. Print 2016 Feb 15.

3.

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Di Pilato M, Mejías-Pérez E, Zonca M, Perdiguero B, Gómez CE, Trakala M, Nieto J, Nájera JL, Sorzano CO, Combadière C, Pantaleo G, Planelles L, Esteban M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1333-42. doi: 10.1073/pnas.1424341112. Epub 2015 Mar 4.

4.

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.

5.

Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M.

J Virol. 2012 May;86(9):5026-38. doi: 10.1128/JVI.06684-11. Epub 2012 Mar 14.

6.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

7.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
8.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.

J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24.

9.

MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M.

Curr Gene Ther. 2011 Jun;11(3):189-217. Review.

PMID:
21453284
10.

T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.

Mónaco DC, Rodríguez AM, Pascutti MF, Carobene M, Falivene J, Gómez A, Maeto C, Turk G, Nájera JL, Esteban M, Gherardi MM.

PLoS One. 2011 Feb 18;6(2):e17185. doi: 10.1371/journal.pone.0017185.

11.

Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence.

Domingo-Gil E, Toribio R, Nájera JL, Esteban M, Ventoso I.

PLoS One. 2011 Feb 2;6(2):e16711. doi: 10.1371/journal.pone.0016711.

12.

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.

Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M.

Vaccine. 2011 Feb 4;29(7):1504-13. doi: 10.1016/j.vaccine.2010.12.016. Epub 2010 Dec 21.

PMID:
21182993
13.

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

García-Arriaza J, Nájera JL, Gómez CE, Sorzano CO, Esteban M.

PLoS One. 2010 Aug 24;5(8):e12395. doi: 10.1371/journal.pone.0012395.

14.

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Nájera JL, Gómez CE, García-Arriaza J, Sorzano CO, Esteban M.

PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406.

15.

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Guerra S, González JM, Climent N, Reyburn H, López-Fernández LA, Nájera JL, Gómez CE, García F, Gatell JM, Gallart T, Esteban M.

J Virol. 2010 Aug;84(16):8141-52. doi: 10.1128/JVI.00749-10. Epub 2010 Jun 9.

16.

Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B.

Rodríguez AM, Turk G, Pascutti MF, Ferrer F, Nájera JL, Mónaco D, Esteban M, Salomón H, Calamante G, Gherardi MM.

Virus Res. 2009 Dec;146(1-2):1-12. doi: 10.1016/j.virusres.2009.08.004. Epub 2009 Aug 26.

PMID:
19715734
17.

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

Gómez CE, Nájera JL, Sánchez R, Jiménez V, Esteban M.

Vaccine. 2009 May 21;27(24):3165-74. doi: 10.1016/j.vaccine.2009.03.049. Epub 2009 Apr 8.

PMID:
19446187
18.

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

Gómez CE, Nájera JL, Krupa M, Esteban M.

Curr Gene Ther. 2008 Apr;8(2):97-120. Review.

PMID:
18393831
19.

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.

Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, Gómez CE, Nájera JL, Jiménez V, Esteban M, Heeney JL.

J Virol. 2008 Mar;82(6):2975-88. doi: 10.1128/JVI.02216-07. Epub 2008 Jan 9.

20.

Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections.

Domingo-Gil E, Pérez-Jiménez E, Ventoso I, Nájera JL, Esteban M.

J Virol. 2008 Jan;82(1):254-67. Epub 2007 Oct 24.

21.

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice.

Gómez CE, Nájera JL, Domingo-Gil E, Ochoa-Callejero L, González-Aseguinolaza G, Esteban M.

J Gen Virol. 2007 Sep;88(Pt 9):2473-8.

PMID:
17698656
22.

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

Guerra S, Nájera JL, González JM, López-Fernández LA, Climent N, Gatell JM, Gallart T, Esteban M.

J Virol. 2007 Aug;81(16):8707-21. Epub 2007 May 30.

23.

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.

PMID:
17224219
24.

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.

PMID:
17113200
25.

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.

Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM, Esteban M.

J Virol. 2006 Jun;80(12):6033-47.

26.

Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.

Guerra S, López-Fernández LA, Pascual-Montano A, Nájera JL, Zaballos A, Esteban M.

J Virol. 2006 Jan;80(2):985-98.

Supplemental Content

Loading ...
Support Center